Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more
Island Pharmaceuticals Ltd (ILA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.237x
Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) has a cash flow conversion efficiency ratio of -0.237x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.69 Million) by net assets (AU$7.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Island Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Island Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Island Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KB No.2 Special Purpose Acq
KQ:192250
|
-0.002x |
|
Gowing Bros Ltd
AU:GOW
|
-0.003x |
|
Hauman Technologies
TWO:6218
|
-0.008x |
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
-0.007x |
|
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
|
-0.031x |
|
ORIENTBIO Inc.
KO:002630
|
0.001x |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
0.079x |
|
Revivegen Co., Ltd.
TWO:7578
|
0.014x |
Annual Cash Flow Conversion Efficiency for Island Pharmaceuticals Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Island Pharmaceuticals Ltd from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$7.16 Million | AU$-2.77 Million | -0.387x | +81.44% |
| 2023-12-31 | AU$1.52 Million | AU$-3.16 Million | -2.084x | -37.34% |
| 2022-12-31 | AU$1.79 Million | AU$-2.71 Million | -1.517x | -248.92% |
| 2021-12-31 | AU$4.32 Million | AU$-1.88 Million | -0.435x | -196.57% |
| 2020-12-31 | AU$6.40 Million | AU$-938.24K | -0.147x | -702.06% |
| 2019-12-31 | AU$-657.00 | AU$-16.00 | 0.024x | -- |